MP680THE EFFECT OF VITAMIN D SUPPLEMENTATION ON RESPONSE TO HEPATITIS B VACCINATION IN DIALYSIS PATIENTS - AN OPEN LABEL PILOT STUDY

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii681-iii681
Author(s):  
Hildegard Hafner-Giessauf ◽  
Sabine Horn ◽  
Hannelore Sprenger-Maehr ◽  
Kathrin Eller ◽  
Alexander Rosenkranz ◽  
...  
Keyword(s):  
Vitamin D ◽  
Pilot Study ◽  
Hepatitis B ◽  
Vitamin D Supplementation ◽  
Hepatitis B Vaccination ◽  
Dialysis Patients ◽  
Open Label

Effect of vitamin D level on the immunogenicity to hepatitis B vaccination in dialysis patients

2016 ◽  
Vol 35 (1) ◽  
pp. 67-71 ◽  
Author(s):  
Rajesh Jhorawat ◽  
Shailendra Jain ◽  
Ajay Pal ◽  
Sandeep Nijhawan ◽  
Pankaj Beniwal ◽  
...  
Keyword(s):  
Vitamin D ◽  
Hepatitis B ◽  
Hepatitis B Vaccination ◽  
Dialysis Patients

scholarly journals Effect of vitamin D supplementation on thyroid autoimmunity among subjects of autoimmune thyroid disease in a coastal province of India: A randomized open-label trial

2020 ◽  
Vol 61 (5) ◽  
pp. 237
Author(s):  
KishoreKumar Behera ◽  
GautomKumar Saharia ◽  
Debasish Hota ◽  
DurgeshPrasad Sahoo ◽  
Madhusmita Sethy ◽  
...  
Keyword(s):  
Vitamin D ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Thyroid Autoimmunity ◽  
Vitamin D Supplementation ◽  
Open Label ◽  
Autoimmune Thyroid ◽  
Coastal Province ◽  
Open Label Trial

scholarly journals Effects of vitamin D supplementation on red cell indices and cytokines in patients with thalassemia: An open-label randomized clinical trial

2019 ◽  
pp. 170-179
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Randomized Clinical Trial ◽  
Thalassemia Major ◽  
Vitamin D Supplementation ◽  
Beta Thalassemia ◽  
Red Cell ◽  
Open Label ◽  
Hematological Indices ◽  
Red Cell Indices

Background and aim Deficiency of vitamin D is known as a health problem all over the world and a recognized clinical complication of beta thalassemia patients. Vitamin D acts as a hormone at the nuclear receptor rendering it a beneficial medication for a number of diseases. It is believed that vitamin D is important in the modulation of the inflammation system by regulating the formation of inflammatory cytokines and immune cells. This study aimed to investigate the effect of vitamin D supplementation on the red cell indices and cytokines levels in patients with beta thalassemia major, in an open label randomized clinical trial. Patients and Methods: this study performed an open-label randomized clinical trial in patients with beta thalassemia major. Forty-six patients completed the eight weeks clinical trial and were allocated to administer oral vitamin D3 supplement of 100,000 IU every two weeks as an add-on treatment. During the study, hematological indices, serum iron, ferritin, vitamin D, calcium and inflammatory markers (interleukin-6, interleukin-2 and interleukin-10) were evaluated before (at baseline) and after vitamin D supplementation for 8 weeks. Results: Vitamin D3 supplements significantly decreases interleukin-6 levels and elevates the serum levels of anti-inflammatory cytokines IL-2 and IL-10, it also significantly reduced serum ferritin level, but it did not alter the hematological indices. Conclusion: Our results suggest that administration of vitamin D has a potential anti-inflammatory role in beta thalassemia patients and reduces serum ferritin levels, which may reduce the burdens of iron overload in thalassemia patients.

Effect of topical vitamin D on chronic kidney disease-associated pruritus: An open-label pilot study

2015 ◽  
Vol 42 (8) ◽  
pp. 800-803 ◽  
Author(s):  
Kyung Eun Jung ◽  
Yu Ri Woo ◽  
Joong Sun Lee ◽  
Jong Ho Shin ◽  
Jin Uk Jeong ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Pilot Study ◽  
Kidney Disease ◽  
Open Label

scholarly journals Hepatitis B Response of Premature Infants after Primary and Booster Immunisation with a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Poliovirus/Haemophilus InfluenzaeType B Vaccine

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Felix Omeñaca ◽  
Jose Garcia-Sicilia ◽  
Reyes Boceta ◽  
Pilar García-Corbeira
Keyword(s):  
Birth Weight ◽  
Hepatitis B ◽  
Premature Infants ◽  
Geometric Mean ◽  
Full Term ◽  
Hepatitis B Vaccination ◽  
Gestational Length ◽  
Open Label ◽  
Term Infants ◽  
Hepatitis B Antigen

A range of schedules are recommended for hepatitis B vaccination of premature infants. This open-label study (217744/083) compared the immune response of premature (N=94) and full-term infants (N=92) to hepatitis B antigen following primary administration of hexavalent DTPa-HBV-IPV/Hib vaccine at 2–4–6 months and a booster dose at 18 months. Anti-HBsAg antibodies were determined before and one month after primary and booster doses. There were no significant differences in postprimary seroprotection rates (anti-HBsAg >10 mIU/mL; preterm 93.4%; full-term 95.2%) or geometric mean concentrations (634 versus 867 mIU/ml), and neither appeared to be related to gestational length or birth weight. Prebooster seroprotection rates were 75 and 80.6%, respectively. Six premature infants did not respond to primary and booster doses. Primary and booster vaccinations with DTPa-HBV-IPV/Hib elicit satisfactory anti-HBsAg responses in preterm infants, which are not influenced by gestational age or birth weight. This schedule and vaccine will greatly facilitate the immunisation of premature infants.

Hepatitis B Vaccination in Dialysis Patients and Nutritional Status

Nephron ◽  
1992 ◽  
Vol 61 (3) ◽  
pp. 266-268 ◽  
Author(s):  
M. Lombardi ◽  
F. Pizzarelli ◽  
M. Righi ◽  
T. Cerrai ◽  
P. Dattolo ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Nutritional Status ◽  
Hepatitis B Vaccination ◽  
Dialysis Patients
Sign in / Sign up

Export Citation Format

Share Document